strong>Daiichi Sankyo Co. Ltd., of Tokyo, and its Plexxikon Inc. unit said The New England Journal of Medicine published clinical trial results demonstrating that investigational drug PLX3397, an oral targeted CSF-1R inhibitor, induced prolonged tumor regressions in most patients with tenosynovial giant cell tumor (TGCT), a rare, locally aggressive neoplasm of the joint or tendon sheath.